 PHILADELPHIA, March 10, 2021 PRNewswire -- Lannett Company, Inc. NYSE: LCI today announced that it recently received feedback from the U.S. Food and Drug Administration FDA regarding biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies HEC. Lannett sought and received comments from the FDA related to the pivotal trial protocol and statistical analysis plan SAP for the development program. 